UPDATE 1-Regeneron Pharma expects slowing Eylea sales, shares slip

Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc reported a lower-than-expected profit for the first time in four quarters and forecast slowing sales growth for its blockbuster eye drug this year, sending its shares down 7.8 percent in premarket trading.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.